Effects of early discontinuation of adjuvant chemotherapy (EDAC) and the timing of treatment on outcomes in patients with early-stage pancreatic cancer (ESPC): Result from a population-based retrospective cohort study.
Javeria Muhammadzai(University of Saskatchewan), Shahid Ahmed(Emory University), Mike Moser(Roswell Park Comprehensive Cancer Center), Yigang Luo(University of Saskatchewan), Donald G. Gardiner(University of Saskatchewan), Gavin Beck(University of Saskatchewan), Osama Ahmed(University of Saskatchewan), John M. Shaw(University of Saskatchewan), Kamal Haider(University of Saskatchewan), Adnan Zaidi(University of Saskatchewan), Mussawar Iqbal(University of Saskatchewan), Bryan Brunet(University of Saskatchewan), Dueck Dorie-Anna(Saskatchewan Cancer Agency), Haji Chalchal
Cited by 0
Related Papers
<i>K-ras</i> Mutations and Benefit from Cetuximab in Advanced Colorectal Cancer
|New England Journal of Medicine|2008|3.6k
Obesity and Cancer: A Current Overview of Epidemiology, Pathogenesis, Outcomes, and Management
|Cancers|2023|640
Gallbladder Cancer in the 21st Century
|Journal of Oncology|2015|301
A Randomized Clinical Trial of Granulocyte Transfusions for Infection in Acute Leukemia
|New England Journal of Medicine|1977|299
The Genotype-Tissue Expression (GTEx) project
|Nature Genetics|2013|266